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A schedulie of high-dose chenotherapy (HDC) consisting of nlphaln (140mg m-)
phls VP16 (2.5gmm) given over 12-18 h togethr with autologous non-cryopreserved autologous bone
marrow tranplant (ABMT) was used for tretment of relpsed (37 patients) and refractory (sven patients)
patients and as first-ine treatment (four patiets) for poor-prognosis Hodgkin's dis. Two patients had a
seond HDC-ABMT after relas following HDC-ABMT, givig a total of 50 poceues among 48
patients. The roovey rate was 98% with a plet rsponse rate of the Hodgkin's disea of
>900/.. Factors sigificanty influencing response rate wre performanc sts and the presen of liver
involvement Thirty-nine patets are afive, with 37 in continuous The duratio of
survival and median duratio of n have not becn reach at a m an follow-p time of 45 months.
Advers prognsic factors for were disea staus at the time of HDC-ABMT (refractory versus
elape, with primarily refractory pats showing signicantly poor survival) and the presec of liver
invovment. High-dose eotherapy with short-duratn apy and non-cryopreserved bone marrow
is an cffctive and safe tatment modality for paints with relapsed and poor-prognosis Hodgkin's
disease.
High-dose chemotherapy with autologous marrow rescue has
now been largely apted as the treatment of choice for
rapidly relpsing and refractory Hodgkin's diseas (HD).
However, the optimum regimen and timing of the procedure
have yet to be ehxcidated. The majority of centres utilise
complx involving initial cytoreduction with con-
ventional dose chemotherapy, followed by marrow harvesting
with cryopreservation, and then a 3-5 day regmen of high-
dose chemotherapy (Carella et al., 1985; Chopra et al., 1993).
While the reported response rates for such rgmens are
excellent, a relatively high i of toxic death occurs,
espially with treatment rgmens using carmustin. There is,
moreover, no evidence that either initial cytoreduction or
prologed treatment schedules are required in order to
achieve either response or prolonged survival in Hodgkin's
disease. While response to cytoreductive therapy does appear
to offer prognostic information (Sullivan et al., 1986; Grib-
ben et al., 1989; Carella et al., 1991a), lack of response to
cytoreduction with conventional dose treatment should not
preclude ABMT in these patients. Although complete res-
ponses are more frequent in chemotherapy-senstive patients
a proportion of patients refractory to conventional dose
chemotherapy do appear to achieve prolonged CR with high-
dose therapy, which, in these patients, appears to be the only
potentally curative treatment option.
Recent studis suggest that patients with poor-prognosis
HD may be defined ab inito (Strauss et al., 1990; Proctor et
al., 1992). It has been suged that such patients may be
candidates for HDC-ABMT as consolidation treatment (Car-
ella et al., 1991b). It should, however, be pointed out that by
selecting patients who have achieved complete remission
(CR) with conventional dose therapy for consolidation with
HD-ABMT a different prognostic group is being studied. If
HDC-ABMT has a role in poor-prognosis HD it will be best
defined by using such therapy as first-line treatment.
We report here a study of 48 patients in whom HDC-
ABMT was used as the first-line treatment approach for
relapsed or refractory disease or as primary treatment for
patients presenting with poor-prognosis Hodgkin's disease.
lTbe treatment regimen cons of short-duration chemo-
therapy with high-dose m Iphaan plus etoposide with
unmaniplated non-crYOPrerVed bone marrow given for
haematolojia rescue.
PatieU
ElgibiUty criteria
From January 1988 until January 1993 48 patients fulfiled
the eligibility criteria which included (1) age kss than 55
years, (2) first relapse less than 12 months from diagnosis, (3)
second or subsequent relapse, (4) faiure to respond to con-
ventional dose induction regimens, (5) patients with initial
prsentation with poor histological subtype (mixed cellularity
or lymphocyte deplted) extensive stage 3 or 4 and bulky
disease (>5 cm) with B symptoms and (6) relapse after CR
with previous ABMT. Marrow infiltration and performance
status at tansplantation were not nsarily exclusion
criteria.
Patients with poor-prognosis primary disease who required
urgent therapy for bulky obstructive disease could receive
one course of conventional dose combination cytotoxic
therapy prior to enrolment.
All patients gave informed consent, and the study was
carried out in accordance with the principles of the Declara-
tion of Helsinki.
Patient characteristic are shown in Tables I and H.
Marrow harvest andcondtiornig reginen
Marrow (10 ml kg-' body weight) was harvested under
general ana a into heparinised M199 culture medium
[marrow-culture medium, 1:1 (v/v)] and stored at 4-C. On
recovery from anaeshsia the patient was returned to the
ward, where melphalan 140 mgm-2 (as a 1 h infusion) and
etoposide 2.5gm-2 (infused at the rate of 500mgl1'h-')
were adminiseed intravenously through a centrally placed
Hickman catheter, with attention to fluid blance. Twenty-
four hours after the completion of the chemotherapy the
marrow was reinfused through the central line, after warmng
to 3rC. Two patients who achieved CR after HD-ABMT
underwent a second procedure identical to the first (at 10
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Table I High-dose melphalan plus VP16 with non-cryopreserved
autologous bone marrow transplantation (ABMT) for Hodgkin's
disease: patient and initial disease characteristics
Nwnber Per cent
Relapsed and refractory patients
Male 29 66
Female 15 34
Relapsed 37 84
Refractory 7 16
Disease stage at initial diagnosis
II 8 18
III 18 41
IV' 18 41
Systemic symptoms at initial diagnosis
A 1 2
B 43 98
Disease bulk at initial diagnosis
Bulky 43 98
Non-bulky 1 2
Initial treatment for Hodgkin's disease
MOPP 15 34
MOPP/ABVD 12 27
MOPP, salvage ABVD 13 30
.2 salvage regimens 4 9
Total nodal irradiation 12 27
Ethnic group
Black 12 27
White 32 73
Median time (months) to first relapse
(±s.d. range) 14 (2-35)
Poor-prognosis HD receiving primary HDC+ABMTb
Female 1 25
Male 3 75
Stage III 2 50
Stage IV 2 50
B symptoms 4 100
Black 4 100
'Seven patients had marrow involvement at initial presentation.
bOf the four patients receiving primary treatment with BMT, two
received one cycle of MOPP for debulking prior to BMT.
months and 12 months post initial HDC-ABMT) following
relapse of the disease. The inclusion of these two patients
resulted in 50 HDC-ABMT procedures in 48 patients.
In two patients, both of whom had marrow infiltration
prior to transplantation, interferon-a (Intron A, Scherag SA)
20 million units was added to the bag at harvesting and
marrow was separated and nucleated cells were cultured in
M199 medium + 20% autologous serum in 180 cm2 (Life cell
Tissue Culture Flask; Fenwall Laboratories, Deerfield IL,
USA) for 96h at 37C in 5% carbon dioxide. The mean
number of nucleated cells infused was 2.77 x 10 kg-' with
viability >85%. Further details are shown in Table III.
Patients were discharged 24 h after receiving the marrow
reinfusion, and were followed as outpatients on a daily or
alternate-day basis until either neutropenic pyrexia or severe
mucositis occurred. All patients required readmission by day
8, and thereafter remained in hospital until recovery of the
neutrophil count to s 500. Although patients did not
routinely receive growth factors, the option was available to
use recombinant granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) as salvage therapy if engraftment did
not occur by day 28.
Supportive care
Patients received single donor irradiated platelets and filtered
red cell transfusions as required, and all patients received
prophylactic ciprofloxacin by mouth when neutropenia
occurred. While in hospital, patients were nursed in single-
bed private wards with reverse barrier nursing. Laminar
airflow conditions were not used. Empirical antibiotic and
Table H High-dose melphalan plus VP16 with non-cryopreserved
ABMT for Hodgkin's disease: characteristics at first BMT
Number Per cent
Stage
III 20 42
IV 28 58
B symptoms 48 100
Bulky disease 26 54
Non-bulky disease 22 41
Histological subtype
NS 23 48
MC 17 35
LD 8 17
Site of involvement
Nodal/spleen 21 44
Liver 9 19
Lung 14 29
Marrow 4 8
CNS 1 2
Number of extranodal sites
1-2 33 69
2 15 31
Haemoglobin (g dl-')
.10 40 83
<10 8 17
Lymphocyte count ( x 109l-')
.1.5 36 75
<1.5 12 25
Performance status (WHO)
I 12 25
2 25 52
3 11 23
Mean age
±s.d. (range) 31 4 (17-49) years
NS, nodular sclerosis; MC, mixed cellularity; LD, lymphocyte
depleted.
Table I High-dose melphalan plus VP16 with non-cryopreserved
ABMT for Hodgkin's disease: marrow collection data
At marrow
collection At transplat
Mean ± s.d.
Total nucleated cells x IO8kg' 2.97 ± 1.3 2.77 ± 1.1
CD34+ cellsx 106 kg-2 12.9 ± 5.9 12.3 ± 5.1
Percentage viability 93 ± 3 87 ± 2
Mean storage time±s.d. (hr - 36±4
Forty-eight patients received 50 ABMTs. 'Bone marrow of two
patients with marrow involvement at the time of collection had in
vitro bone marrow culture for %9h with addition of IFN-a 20mU.
antifungal therapy was utilised as indicated for neutropenic
sepsis.
Response criteria
All patients were restaged 3 months after transplantation,
and standard criteria to assess response were utilised.
Statistical analysis
Response, toxic death, overall survival from date of trans-
plantation and event-free survival were analysed using SAS
statistical software. Factors which were examined for
influence on response rate included sex, histological subtype,
presence or absence of systemic symptoms, haemoglobin con-
centration, lymphocyte count, number of extranodal sites,
presence or absence of marrow involvement, disease bulk,
number of relapses, relapse status (relapsed versus refractory
disease), the presence of liver involvement and performance
status. Survival curves were estimated using the method of
Kaplan and Meier, and were compared using the log-rank
statistic.528 L.K. SEYMOUR et al.
Table IV High-dose melphalan plus VP16 with non-cryopreserved
ABMT for Hodgkin's disease: haematological response
Number Per cent
Haematological recoverya 49 98
Mean red cell transfusion requirement 4 (±2)
Mean platelet transfusion requirement 4 (±2)
Median time to haematological
recovery (days)
Neutrophils > 1.0 x 1091-' 22
Platelets _40 x 1091-l 25
'Out of 50 bone marrow transplant procedures.
Table V High-dose melphalan plus VP16 with non-cryopreserved
ABMT for Hodgkin's disease: toxicity
Number Per cent
Early death 1 2
Intracerebral haemorrhage 1 2
Renal dysfunction 2 4
Nausea (grade 3-4) 36 75
Vomiting (grade 3-4) 36 75
Grade 3-4 mucositis 48 100
Neutropenic fever 48 100
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Figre I Actuarial survival of all patients with relapsed/re-
fractory Hodgkin's disease treated with single high-dose melpha-
lan (140mgm-2) and VP16 (2.5gm-) plus non-cryopreserved
autologous bone marrow transplantation.
I.u -
Results
Response to treatment
Forty-three of 48 patients (90%) achieved a complete res-
ponse (CR), one (2%) patient achieved a partial response
(PR), three patients showed no response to therapy (NR),
and one patient was not eligible for evaluation (NE) owing
to early death. Response rate according to a number of
transplant procedures (50 procedures among 48 patients) was
CR 43/50 (86%), PR 3/50 (6%), NR 3/50 (6%) and not
evaluable 1 (2%). The two patients who relapsed after
previous BMT both achieved only PR with the second trans-
plant procedure. Of the factors examined for prognostic
influence, only performance status (X2 = 14.61, P = 0.002)
and liver involvement (X2 = 11.58, P= 0.003) were shown to
significantly influence response to HDC-ABMT.
Toxicity
Haematological recovery was documented in 49/50 (98%)
transplant procedures (Table V). The one exception was a
patient who died at day 10 post chemotherapy from multi-
organ failure related to chemotherapy drug toxicity. This
patient was classified as non-evaluable for haematological
recovery because of early death.
One patient who was transplanted with extensive disease
and a performance status of 3 died of early complications
prior to haematological recovery. No other procedure-related
mortality was experienced. Two patients had moderate rever-
sible renal toxicity and one patient had a minor intracerebral
haemorrhage, from which he made a full recovery (Table
V).
All patients experienced severe grade 3-4 mucositis, which
was usually the major cause of readmission to hospital. This
necessitated the use of both intravenous analgesia and fluid
for 3-4 days, and occasionally the use of hyperalimentation.
All patients experienced grade 4 neutropenia and thrombo-
cytopenia. The mean time to neutrophil count recovery
() 1 x 109) was 23 ± 7 days (range 13-42 days) and the
mean time to platelet recovery () 40 x 109) was 27 ± 9 days
(range 15-60 days). All patients developed neutropenic fever
requiring broad-spectrum intravenous antibiotics.
Survival
The median survival has yet to be reached. Actuarial survival
is shown in Figure 1. Factors analysed for influence on
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Figre 2 Influence of hepatic involvement on survival ofpatients
with refractory relapsed HD treated with high-dose melphalan
+ VP16 and ABMT. (0) patients without hepatic involvement;
(0) patients with hepatic involvement (P = 0.05, log-rank).
survival included all those analysed for response to treat-
ment. Univariate analysis indicated that refractory disease at
transplantation (.X = 9.12, P = 0.01), hepatic involvement
(Figure 2) (X2 = 3.76, P = 0.05) and performance status
(X2 = 3.72, P = 0.05) were the only significant predictors of
survival. The number of relapses prior to transplantation was
not a significant factor predicting for either response or
survival duration. The presence of marrow infiltration, either
at time of transplantation or at initial presentation, also
failed to influence survival. Thirty-nine patients are alive and
37 of these remain in unmaintained remission. Eight patients
have relapsed and died of progressive disease, including two
patients who received second ABMTs. Both of these patients
achieved a second CR with survivals thereafter of 6 and 12
months.
Although the management of Hodgkin's lymphoma has
achieved substantial success, with the majority of patients,
including even those with extensive disease, attaining durable
complete responses using conventional dose combination
chemotherapy, there remains a significant proportion of
patients who are either refractory to induction therapy or
who relapse soon after achieving response. In addition,
1 n-
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recent studies suggest that patients who have a poor prog-
nosis with conventional dose chemotherapy (Fisher et al.,
1979) may be defined by prognostic criteria which include
not only stage but also non-stage-related factors such as
histological subtype, age, disease bulk, haemoglobin level and
total lymphocyte count (Proctor et al., 1992).
Non-cross-resistant multidrug chemotherapy regimens offer
some hope of salvage in these patients, but the long-term
disease-free remission and ultimate cure rates remain low.
The most promising results have been obtained with the use
of high-dose chemotherapy conditionig regmens with
autologous bone marrow rescue (HDC-ABMT). Such poor-
prognosis patients may well be candidates for early HDC-
ABMT. Early reports, even in patients with refractory
disease, suggested that complete response (CR) rates in
excess of 50% could be achieved (Carella et al., 1985).
Although toxic death rates were fairly high in initial studies
(3-80%) (Lu et al., 1983; Goldstone et al., 1985), this could
probably be attributed to the fact that the majority of the
reported patients had been extensively pretreated and were
largely in resistant relapse. In addition, many patients had
been previously exposed to thoracic radiotherapy and/or to
other agents causing pulmonary toxicity. Such patients have
a significantly increased risk ofdeveloping respiratory failure
due to infection and pulmonary alveolar haemorrhage (Jules-
Elysee et al., 1992).
More recent studies such as that from Chopra et al. (1993)
using a combination of BCNU, etoposide, cytosine arabino-
side and melphalan (BEAM) have reported improved results
with an approximately 10% prevalence of toxic death and a
50% actuarial 5-year relapse-free survival. Interestingly, these
investigators reported a poorer survival not only in patients
with refractory disease, but also those in first relapse, with
patients in second and third relapse having a superior
relapse-free survival.
HDC-ABMT appears to be relatively well tolerated, with
good quality of life being attained, especially in responding
patients (Chao et al., 1992). Indeed, 96% of patients indicate
that they would be willing to undergo the procedure a second
time if necessary (Vose et al., 1992).
To a large extent, HDC-ABMT procedures have utilised
BCV- or BEAM-like regimens given over a number of days
and necessitating cryopreservation of the autologous marrow
(Reece et al., 1991). Optimum treatment regimens and
schedules remain to be defmed however. Treatment program-
mes utilising agents such as melphalan and etoposide, which
have short half-lives, can be administerd in less than 24 h
with the potential advantage of not requiring cryopreserva-
tion ofmarrow (Carella et al., 1985; Taylor et al., 1993), thus
making the procedure less costly and technically less demand-
ing.
There is also controversy as to whether HDC-ABMT
should be used as the initial treatment approach for relapsed
and refractory disease, or whether cytoreductive therapy
should be attempted prior to ABMT. An advantage of initial
cytoreduction is that chemosensitivity can be assd prior
to transplantation. Numerous investigators have found sen-
sitive relapse to be predictive of remission rate and longer
disease-free survival following HDC-ABMT (Crump et al.,
1993b). However, if the approach is to be HDC-ABMT
whatever the outcome of cytoreductive therapy, an obvious
disadvantage of attempting retreatment prior to HDC-
ABMT would be a more heavily pretreated patient undergo-
ing ABMT, with a resultant increase in morbidity and pos-
sibly mortality.
The regimen that we have utilised has a number of advan-
tages. No speciaised marrow handling equipment, cryopre-
servation or storage techniques are required, as the marrow is
merely stored at 4-C and reinfused 36-48 h after harvesting.
The chemotherapy regimen is uncomplicated and can be
administered in a single day, thus allowing the discharge of
the patient for 4-7 days prior to the onset of mucositis and
neutropenia, with resultant cost savings.
Although morbidity from severe mucositis was high, occur-
ring in all patients, it generally necessitated an inpatient stay
of between 7 and 14 days only, and was easily managed.
Only one early death occurred, and other morbidity was
generally self-limiting.
Whether the use of bone marrow culture with interferon
alpha added anything to the treatment of patients with mar-
row involvement at the time of BMT cannot be determined
from the current study. The presence of marrow involvement
is obviously a worrying feature with the possibility of return-
ing a contaminated graft. Other possible methods of dealing
with this problem may be some positive sekction procedure,
selecting for multipotent (stem cell) bone marrow precursors
only. However, the utility of and even theoretical back-
ground for such procedures must wait for a clearer definition
of the characteristics of the malignant cell in HD.
One further aspect that deserves comment is the question
of the use of bone marrow as against peripheral blood
precursor cells (PBPCs) for effecting haematological rescue.
A number of studies have shown rapid haematological re-
covery following HDC with growth factor-mobilsed PBPCs
in a variety ofhaematological and non-haematological malig-
nancies (To et al., 1992; Crump et al., 1993a; Pettengel et al.,
1993a, b). The studies of Pettengel et al. suggest more rapid
haematological engraftment with PBPCs, but whether BMT
or PBPCs is the most cost-effective rescue procedure in
patients with HD requires further study.
Despite these provisos it should, however, be pointed out
that a 90% complete response rate was achieved and median
survival and median time to treatment failure have yet to be
reached. Whie a poor performance status and hepatic
involvement appeared to be adverse prognostic factors for
response, a number of patients with these features did
achieve CR and substantial disease-free survival. Relapse
status at time of transplant, whether first, second or third
relapse, did not appear to affect either response rates or
survival.
The regimen and therapeutic approach described appears
to offer response rates and survival at least equivalent to
those reported in the literature, and is in addition brief and
uncomplicated, requiring little speialised equipment and a
shortened inpatient hospital stay. There appears to be no
advantage to initial cytoreductive therapy in patients with
Hodgkin's disease who require ABMT and high-dose chemo-
therapy, except in patients who require urgent therapy for
obstructive complications.
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